PGT-Monogenic Disorder

Ensuring a healthy and successful pregnancy

What is PGT-M

PGT-M is an invaluable tool designed to diagnose embryos for hereditary diseases and conditions in families with a known history or with affected children. During PGT-M, embryos generated by IVF are tested for the mutation(s) in which one or both parents are carriers for; only the healthy embryos will be selected for transfer.

Monogenic disorders are common particularly in consanguineous societies, such as the Middle East. Examples of single-gene disorders include:

Sickle Cell Anemia, Beta-Thalassemia

Spinal Muscular Atrophy

Metabolic Disorders

Mitochondrial Disorders

Polycystic Kidney Disease

Indicators of PGT-M

  • A couple with a history of having a child or pregnancy affected by a genetic condition.
  • Both partners being carriers of an autosomal recessive condition, resulting in a 25% risk of passing the genetic disorder to a child 
  • One partner being affected by an autosomal dominant condition, leading to a 50% risk of passing on a genetic disorder 
  • A female partner being a carrier of an X-linked condition, with a 50% risk of male babies being affected 
  • Families opting to perform HLA matching.
  • One or both partners having a mutation associated with susceptibility to a hereditary cancer syndrome

PGT-M and HLA Matching

Cord blood stem cells obtained through hematopoietic stem cell transplantation have the potential to cure genetic anomalies, like Beta-Thalassemia, in family members. HLA matching plays a crucial role in the successful utilization of these cord blood stem cells for treating affected siblings.

 To achieve this, it is recommended that parents undergo an IVF procedure to conceive a second child. The embryos generated from this process will undergo genetic testing using PGT-M, in combination with HLA matching. This comprehensive approach aims to identify a healthy embryo that can serve as a suitable potential donor for their affected sibling, ensuring the best chances for a successful treatment.

PGT-M at Viafet

Since our establishment in 2000, Viafet has been a leader in in-vitro genetic testing and the first in the Middle East to offer Pre-implantation Genetic Testing for monogenic disorders. Our expertise is evident in the successful completion of numerous IVF cycles targeting various monogenic disorders.

PGT-M at Viafet:

Ability to diagnosis any genetic mutation/disease

Expertise in diagnosing over thousands of genetic conditions

Provide accurate and reliable results

Fast turn-around-time

Analysis on Day 3 or Day 5 biopsy for fresh or frozen embryo transfer

Allows a combination of PGT-M and PGT-A from a single biopsy